Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Amneal Pharmaceuticals, Inc.'s Expenses

Comparing cost trends of Halozyme and Amneal over a decade.

__timestampAmneal Pharmaceuticals, Inc.Halozyme Therapeutics, Inc.
Wednesday, January 1, 201433598900022732000
Thursday, January 1, 201536705400029245000
Friday, January 1, 201642077000033206000
Sunday, January 1, 201750747600031152000
Monday, January 1, 201894658800010136000
Tuesday, January 1, 2019127337600045546000
Wednesday, January 1, 2020136413000043367000
Friday, January 1, 2021132469600081413000
Saturday, January 1, 20221427596000139304000
Sunday, January 1, 20231573042000192361000
Monday, January 1, 2024159417000
Loading chart...

Cracking the code

Unveiling Cost Dynamics: Halozyme vs. Amneal

In the ever-evolving pharmaceutical landscape, understanding cost structures is pivotal. Over the past decade, Amneal Pharmaceuticals, Inc. and Halozyme Therapeutics, Inc. have showcased contrasting expense trajectories. Amneal's cost of revenue surged by approximately 368% from 2014 to 2023, reflecting its aggressive market expansion and production scaling. In contrast, Halozyme's expenses grew by nearly 747% during the same period, indicating strategic investments in innovation and development.

A Decade of Financial Evolution

Amneal's cost of revenue consistently climbed, peaking in 2023, underscoring its commitment to broadening its product portfolio. Meanwhile, Halozyme's expenditure spike in recent years highlights its focus on pioneering therapeutic solutions. This financial narrative not only reveals the companies' strategic priorities but also offers investors a lens into their operational efficiencies and market positioning.

As the pharmaceutical industry continues to innovate, these insights provide a window into the fiscal strategies driving two of its key players.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025